LLY

769.57

+0.18%↑

JNJ

151.58

+0.77%↑

NVO

70.24

+0.92%↑

ABBV

184.44

+0.76%↑

UNH

302

+0.8%↑

LLY

769.57

+0.18%↑

JNJ

151.58

+0.77%↑

NVO

70.24

+0.92%↑

ABBV

184.44

+0.76%↑

UNH

302

+0.8%↑

LLY

769.57

+0.18%↑

JNJ

151.58

+0.77%↑

NVO

70.24

+0.92%↑

ABBV

184.44

+0.76%↑

UNH

302

+0.8%↑

LLY

769.57

+0.18%↑

JNJ

151.58

+0.77%↑

NVO

70.24

+0.92%↑

ABBV

184.44

+0.76%↑

UNH

302

+0.8%↑

LLY

769.57

+0.18%↑

JNJ

151.58

+0.77%↑

NVO

70.24

+0.92%↑

ABBV

184.44

+0.76%↑

UNH

302

+0.8%↑

Search

Akebia Therapeutics Inc

Avatud

SektorTervishoid

3.77 5.9

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.48

Max

3.85

Põhinäitajad

By Trading Economics

Sissetulek

29M

6.1M

Müük

11M

57M

Aktsiakasum

0.025

Kasumimarginaal

10.66

Töötajad

181

EBITDA

20M

14M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+83.42% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

324M

935M

Eelmine avamishind

-2.13

Eelmine sulgemishind

3.77

Uudiste sentiment

By Acuity

100%

0%

363 / 381 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Akebia Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. juuni 2025, 19:24 UTC

Suurimad hinnamuutused turgudel

Amgen Expands MariTide Development Plans After Weight-Loss Trial -- Update

23. juuni 2025, 19:07 UTC

Suurimad hinnamuutused turgudel

Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial

23. juuni 2025, 17:29 UTC

Omandamised, ülevõtmised, äriostud

FTC Resolves Antitrust Probe Into Omnicom-Interpublic Merger

23. juuni 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. juuni 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Fears About Israel-Iran Conflict Ease -- Market Talk

23. juuni 2025, 23:39 UTC

Market Talk

Gold Falls After Trump Says Israel, Iran Agree to Cease-Fire -- Market Talk

23. juuni 2025, 23:39 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

23. juuni 2025, 22:53 UTC

Market Talk

Global Equities Roundup: Market Talk

23. juuni 2025, 21:42 UTC

Tulu

KB Home Cuts FY25 Outlook as 2Q Profit, Sales Fall -- Update

23. juuni 2025, 20:50 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

23. juuni 2025, 20:30 UTC

Market Talk

Canada Employment Data May Be Overstating Job Gains -- Market Talk

23. juuni 2025, 20:24 UTC

Omandamised, ülevõtmised, äriostud

Tesla Stock Surges After Musk's Robo-Taxi Rollout. Where Shares Go From Here. -- Barrons.com

23. juuni 2025, 20:16 UTC

Market Talk

U.S. Stocks Climb After Iran's Retaliation Seen As Measured -- Market Talk

23. juuni 2025, 19:22 UTC

Market Talk

Oil Futures Sink As Iranian Retaliation Seen Weak -- Market Talk

23. juuni 2025, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

23. juuni 2025, 18:49 UTC

Market Talk

Gold Ticks Higher in Cautious Trade -- Market Talk

23. juuni 2025, 18:14 UTC

Market Talk

Global Energy Roundup: Market Talk

23. juuni 2025, 18:14 UTC

Market Talk

Treasury Yields, Dollar Little Changed on Iran's Retaliation -- Market Talk

23. juuni 2025, 17:59 UTC

Market Talk

Oil Futures Fall As Iran Fires Missiles At U.S. Bases in Qatar -- Market Talk

23. juuni 2025, 17:25 UTC

Market Talk

Services Lift Mexico's Economic Activity in April -- Market Talk

23. juuni 2025, 17:22 UTC

Market Talk

Weaker Oil Long-Term Looks to Keep a Lid on Grains -- Market Talk

23. juuni 2025, 17:20 UTC

Market Talk

Mexican Inflation Seen Easing in Early June --Market Talk -- Market Talk

23. juuni 2025, 16:27 UTC

Market Talk
Tulu

Commercial Metals Says Tariffs, Interest Rates Won't Drag on Earnings -- Market Talk

23. juuni 2025, 16:23 UTC

Market Talk
Tulu

Commercial Metals Sees Resilient Demand, Eyes Growth as Economic Uncertainty Eases -- Market Talk

23. juuni 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

23. juuni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

23. juuni 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. juuni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

23. juuni 2025, 15:50 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole Didn't Disclose Financial Details

23. juuni 2025, 15:49 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: Impact on Credit Agricole's CET1 Ratio Expected to Be Limited

Võrdlus sarnastega

Hinnamuutus

Akebia Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

83.42% tõus

12 kuu keskmine prognoos

Keskmine 6.75 USD  83.42%

Kõrge 8 USD

Madal 6 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Akebia Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

4

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

2.345 / N/AToetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

363 / 381 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.